Azenta, Inc. logo

Azenta, Inc.

AZTA

NASDAQHealthcareMedical - Instruments & Supplies

Regular session

$33.6242

−$3.7758 · -10.10%

Aug 24, 1:41 PM ET

AZTA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

39

Weakening

Sentiment

54

Mixed

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
John Marotta
Listed since
Feb 2, 1995
Employees
2,900

Market position

Day range

Current $33.6242

52-week range

Current $33.6242

Open
$33.32
Previous close
$37.40
Volume
1.13M
1.19× average
Average volume
948.23K
Average daily volume
Market cap
1.55B USD
Beta
1.38
Market reference 1
50-day average
$27.8364
+20.79% above average
200-day average
$28.1887
+19.28% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.15B USD
P/E (TTM)
-12.23×
P/B (TTM)
1.01×
P/S (TTM)
2.52×
EV / EBITDA
21.18×
Earnings yield
-4.24%
Free cash flow yield
2.92%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
44.05%
Operating margin
-3.49%
Net margin
-20.02%
Return on equity
-3.23%
Return on assets
-2.71%
Return on invested capital
2.11%

Financial health

Debt / equity
0.04×
Current ratio
2.98×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends58%9%-40%-89%Gross margin, FY2021: 41.76%Gross margin, FY2022: 41.52%Gross margin, FY2023: 35.07%Gross margin, FY2024: 44.40%Gross margin, FY2025: 45.52%Operating margin, FY2021: 0.70%Operating margin, FY2022: -4.32%Operating margin, FY2023: -12.36%Operating margin, FY2024: -5.23%Operating margin, FY2025: -1.90%Net margin, FY2021: 21.56%Net margin, FY2022: -77.22%Net margin, FY2023: -2.14%Net margin, FY2024: -28.76%Net margin, FY2025: -9.39%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 41.76%. Gross margin FY2022 41.52%. Gross margin FY2023 35.07%. Gross margin FY2024 44.40%. Gross margin FY2025 45.52%. Operating margin FY2021 0.70%. Operating margin FY2022 -4.32%. Operating margin FY2023 -12.36%. Operating margin FY2024 -5.23%. Operating margin FY2025 -1.90%. Net margin FY2021 21.56%. Net margin FY2022 -77.22%. Net margin FY2023 -2.14%. Net margin FY2024 -28.76%. Net margin FY2025 -9.39%.

Income trends

Revenue

593.82M USD+3.55%

Operating income

−11.27M USD+62.42%

Net income

−55.76M USD+66.18%
Income trends across reported periods774.48M USD336.86M USD−100.75M USD−538.36M USDRevenue, FY2021: 513.7M USDRevenue, FY2022: 555.5M USDRevenue, FY2023: 665.07M USDRevenue, FY2024: 573.45M USDRevenue, FY2025: 593.82M USDOperating income, FY2021: 3.6M USDOperating income, FY2022: −24.02M USDOperating income, FY2023: −82.2M USDOperating income, FY2024: −29.98M USDOperating income, FY2025: −11.27M USDNet income, FY2021: 110.75M USDNet income, FY2022: −428.96M USDNet income, FY2023: −14.26M USDNet income, FY2024: −164.9M USDNet income, FY2025: −55.76M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 513.7M USD. Revenue FY2022 555.5M USD. Revenue FY2023 665.07M USD. Revenue FY2024 573.45M USD. Revenue FY2025 593.82M USD. Operating income FY2021 3.6M USD. Operating income FY2022 −24.02M USD. Operating income FY2023 −82.2M USD. Operating income FY2024 −29.98M USD. Operating income FY2025 −11.27M USD. Net income FY2021 110.75M USD. Net income FY2022 −428.96M USD. Net income FY2023 −14.26M USD. Net income FY2024 −164.9M USD. Net income FY2025 −55.76M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue593.82M USD573.45M USD665.07M USD555.5M USD513.7M USD
Cost of goods sold323.54M USD318.83M USD431.82M USD324.88M USD299.19M USD
Gross profit270.28M USD254.62M USD233.26M USD230.62M USD214.51M USD
Research and development30.39M USD31.52M USD33.96M USD27.54M USD22.41M USD
Selling, general, and administrative251.16M USD253.08M USD281.5M USD227.1M USD188.5M USD
Operating expenses281.55M USD284.6M USD315.45M USD254.64M USD210.91M USD
Interest income18.78M USD33.18M USD43.74M USD20.29M USD632K USD
Interest expense4.59M USD2.04M USD
Depreciation and amortization61.21M USD90.74M USD85.58M USD53.7M USD56.87M USD
Operating income−11.27M USD−29.98M USD−82.2M USD−24.02M USD3.6M USD
Net income−55.76M USD−164.9M USD−14.26M USD−428.96M USD110.75M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+43.15%
11 comparable reports
Latest EPS result
0.16
Estimate 0.11 · Beat by 40.60%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.250.140.03-0.08Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.08, estimate 0.05, surprise +60.00%, Beat. Q2 2025, reported May 7, 2025: actual 0.05, estimate 0.09, surprise -44.44%, Miss. Q3 2025, reported Aug 5, 2025: actual 0.19, estimate 0.13, surprise +46.15%, Beat. Q4 2025, reported Nov 21, 2025: actual 0.21, estimate 0.19, surprise +10.82%, Beat. Q1 2026, reported Feb 4, 2026: actual 0.09, estimate 0.11, surprise -18.18%, Miss. Q2 2026, reported May 6, 2026: actual -0.04, estimate 0.1, surprise -140.00%, Miss. Q3 2026, reported Aug 4, 2026: actual 0.16, estimate 0.114, surprise +40.60%, Beat. Q4 2026, reported Nov 17, 2026: actual —, estimate 0.164, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates167.63M156.56M145.49M134.43MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 147.51M USD, estimate 141.31M USD, surprise +4.39%, Beat. Q2 2025, reported May 7, 2025: actual 143.42M USD, estimate 140.88M USD, surprise +1.80%, Beat. Q3 2025, reported Aug 5, 2025: actual 143.94M USD, estimate 149.38M USD, surprise -3.64%, Miss. Q4 2025, reported Nov 21, 2025: actual 159.19M USD, estimate 156.2M USD, surprise +1.91%, Beat. Q1 2026, reported Feb 4, 2026: actual 148.64M USD, estimate 147.09M USD, surprise +1.06%, Beat. Q2 2026, reported May 6, 2026: actual 144.8M USD, estimate 148.3M USD, surprise -2.37%, Miss. Q3 2026, reported Aug 4, 2026: actual 161.18M USD, estimate 149.31M USD, surprise +7.95%, Beat. Q4 2026, reported Nov 17, 2026: actual —, estimate 160.32M USD, surprise —, Comparison unavailable.

AZTA news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.40

2021 complete year0.0% since 2017

Corporate action history

Dividend

Ex-dividend Dec 2, 2021

$0.10

Quarterly

Record Dec 3, 2021 · Payment Dec 23, 2021

Dividend

Ex-dividend Sep 2, 2021

$0.10

Quarterly

Record Sep 3, 2021 · Payment Sep 24, 2021

Dividend

Ex-dividend Jun 3, 2021

$0.10

Quarterly

Record Jun 4, 2021 · Payment Jun 25, 2021

Dividend

Ex-dividend Mar 4, 2021

$0.10

Quarterly

Record Mar 5, 2021 · Payment Mar 26, 2021

Dividend

Ex-dividend Dec 3, 2020

$0.10

Quarterly

Record Dec 4, 2020 · Payment Dec 17, 2020

Dividend

Ex-dividend Sep 3, 2020

$0.10

Quarterly

Record Sep 4, 2020 · Payment Sep 25, 2020

AZTA peers

ETFs holding AZTA

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research AZTA

research.disclaimer